Cutaneous mucormycosis.
Mucormycosis is an invasive fungal infection caused by fungi of the order Mucorales, mainly affecting immunocompromised patients. Cutaneous mucormycosis is the third most common clinical form of the disease, after pulmonary and rhino-cerebral. The usual factors predisposing to this infection are hematological malignancies and diabetes mellitus, but a significant proportion of patients are immunocompetent. The agents of mucormycosis are ubiquitous in nature and are transmitted to the skin by direct inoculation, as a result of various types of trauma. These include needle sticks, stings and bites by animals, motor vehicle accidents, natural disasters, and burn injuries. The typical presentation of mucormycosis is the necrotic eschar, but it can present with various other signs. The infection can be locally invasive and penetrate into the adjacent fat, muscle, fascia, and bone, or become disseminated. Diagnosis is difficult because of the nonspecific findings of mucormycosis. Biopsy and culture should be performed. The treatment of mucormycosis is multimodal and consists of surgical debridement, use of antifungal drugs (amphotericin B and posaconazole), and reversal of underlying risk factors, when possible. Mortality rates, although lower than in other forms of the disease, are significant, ranging from 4% to 10% when the infection is localized.
1st Department of Propedeutic Medicine, Athens University, Laikon General Hospital, M. Asias 75, Goudi 11527, Athens, Greece. askiada@otenet.gr
Anna
A
Skiada
George
G
Petrikkos
D000935:Antifungal Agents / Q000627:therapeutic use; D003646:Debridement / Q000379:methods; D003881:Dermatomycoses / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D006801:Humans; D009091:Mucormycosis / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D012307:Risk Factors
D000935:Antifungal Agents